Statements (33)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
phosphodiesterase-4 inhibitor |
| gptkbp:approvalYear |
2011
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA |
| gptkbp:ATCCode |
R03DX07
|
| gptkbp:brand |
gptkb:Zoryve
gptkb:Daliresp |
| gptkbp:CASNumber |
162401-32-3
|
| gptkbp:chemicalFormula |
C17H14Cl2F2N2O3
|
| gptkbp:contraindication |
severe liver impairment
|
| gptkbp:developedBy |
gptkb:Nycomed
|
| gptkbp:drugClass |
phosphodiesterase inhibitor
|
| gptkbp:eliminationHalfLife |
17 hours
|
| https://www.w3.org/2000/01/rdf-schema#label |
roflumilast
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
inhibits phosphodiesterase-4
|
| gptkbp:metabolism |
liver
|
| gptkbp:molecularWeight |
403.21 g/mol
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
diarrhea headache weight loss insomnia |
| gptkbp:synonym |
B9302-107
Roflumilastum |
| gptkbp:usedFor |
psoriasis
chronic obstructive pulmonary disease |
| gptkbp:bfsParent |
gptkb:Daliresp
gptkb:PDE4 |
| gptkbp:bfsLayer |
7
|